FDA Approves New Breast Cancer AI Risk Tool

The TumorSight Risk tool evaluates recurrence risk for early-stage breast cancer patients using MRI imaging.

Updated on Oct. 19, 2026 in Cancer

FDA Approves New Breast Cancer AI Risk Tool

Live Poll

Do you trust that new AI diagnostic tools will improve your personal medical care outcomes?

The FDA has granted approval to the TumorSight Risk tool, a new AI system created by SimBioSys. It is designed to assess recurrence risk for patients with early-stage hormone receptor-positive, HER2-negative breast cancer.

Why it matters

The tool offers a significant acceleration in diagnostic speed, providing risk assessments in hours rather than the weeks often required for standard tissue-based testing.

The tool assesses recurrence risk at five and 10 years after diagnosis for a cancer type that accounts for over 70% of U.S. breast cancer diagnoses. Approval followed a study involving more than 2,000 patients.

The players

FDA

The Food and Drug Administration is the federal agency responsible for regulating medical devices and ensuring the safety and efficacy of new health technologies.

SimBioSys

SimBioSys is a medical technology company that focuses on using artificial intelligence to transform cancer care and diagnostic processes.

The details

The technology evaluates recurrence risk by utilizing AI to analyze MRI images, effectively replacing the need for traditional surgical tissue sampling. This approach provides clinicians with critical data to help manage early-stage hormone receptor-positive, HER2-negative breast cancer more efficiently.

The tool assesses the risk of cancer recurrence at five and 10 years after diagnosis.

The Big Picture

This development marks a significant departure from the historical standard of surgical tissue sampling for cancer risk assessment. It moves the field toward non-invasive diagnostic paradigms enabled by artificial intelligence.

Patients may benefit from significantly faster diagnostic timelines, moving from a waiting period of weeks to just hours. This acceleration allows for quicker medical decision-making regarding early-stage treatment plans.

The takeaway

AI-driven diagnostics are transforming patient care by reducing the physical and temporal burdens of traditional testing. Patients should consult with their oncologists to see if non-invasive AI assessments are appropriate for their specific diagnosis.